港股通龍虎榜 | 美團點評繼續受捧
今日南向資金淨流入12.71億元,美團點評繼續受捧,獲淨買入4.21億港元,騰訊控股獲淨買入4.15億港元;小米集團獲淨賣出0.35億港元。


美團點評獲淨買入4.2億港元。美團外賣發佈聲明,表示將更好優化系統,在爲用戶提供準時配送服務的同時,調度系統會給騎手留出8分鐘彈性時間。
騰訊獲淨買入4.14億港元。騰訊發佈了《數字中國指數報告》顯示,中國數字化水平持續增長,全國用雲量也實現了118%的增長,且傳統產業增速尤爲明顯。
信達生物獲淨買入1.52億港元。消息面上,野村發表研究報告指出,信達生物目前已提交了兩個有關信迪利單抗(Sintilimab)新藥申請(NDA)。



(港股通持股比例排行,交易所的數據T+2日結算)
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.